Alector Announces Appointment of Elizabeth A. Garofalo, M.D., to its Board of Directors
28 September 2021 - 10:30PM
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology
company pioneering immuno-neurology, today announced the addition
of Elizabeth (Betsy) A. Garofalo, M.D., to the Company’s Board of
Directors. Dr. Garofalo is a veteran biopharmaceutical executive
with more than 25 years of experience in global clinical
development and regulatory affairs, with a focus on neurology.
“Betsy is a highly-regarded leader with unmatched clinical
development experience, particularly in neurodegenerative disease
indications. As we advance our pipeline of novel immuno-neurology
therapeutics into later-stage clinical trials, her expert
perspective in neurology drug development will be a strong and
valued addition to our team,” said Arnon Rosenthal, Ph.D., Chief
Executive Officer of Alector.
Since 2016, Dr. Garofalo has served as the principal for EAG
Pharma Consulting LLC. Previously, Dr. Garofalo worked for
Novartis, serving as Senior Vice President and Global Head of
Clinical Development and as a member of its Global Development
Leadership Team; she was also Chair of the Novartis Portfolio
Stewardship Board and Co-Head of the Novartis Neuroscience
Franchise. Prior to Novartis, Dr. Garofalo held several leadership
positions, including Global Therapeutics Area Leader, CNS at
Astellas; Ann Arbor Site Head, Worldwide Regulatory Affairs at
Pfizer; and Ann Arbor Site Head of Neuroscience at Pfizer. Dr.
Garofalo currently serves on the Boards of Xenon Pharmaceuticals,
Inc., Exicure, Inc. and Acadia Pharmaceuticals Inc. She is also
Chair of the Pediatric Oversight Committee at the Institute for
Advanced Clinical Trials in Children and is the Chair of the
Business Advisory Board for the Epilepsy Foundation of America. Dr.
Garofalo holds an M.D. from the Indiana University School of
Medicine and completed fellowships in pediatric neurology and
epilepsy at the University of Michigan Medical School.
“Alector is well-positioned to be a leader in the neurology
space, with a promising and productive platform that leverages an
understanding of the brain’s immune system and the genetic
underpinnings of degenerative diseases to advance clinical programs
aimed at addressing significant problems associated with diseases
such as frontotemporal dementia, Alzheimer’s, and ALS,” said Dr.
Garofalo. “I look forward to working with Arnon, the leadership
team, and the Board to support the continued growth of Alector’s
neurology programs to help make a meaningful difference in the
lives of patients.”
About AlectorAlector is a
clinical-stage biotechnology company pioneering immuno-neurology, a
novel therapeutic approach for the treatment of neurodegenerative
diseases. Immuno-neurology targets immune dysfunction as a root
cause of multiple pathologies that are drivers of degenerative
brain disorders. Alector has discovered and is developing a broad
portfolio of innate immune system programs, designed to
functionally repair genetic mutations that cause dysfunction of the
brain’s immune system and enable the rejuvenated immune cells to
counteract emerging brain pathologies. Alector’s immuno-neurology
product candidates are supported by biomarkers and target
genetically defined patient populations in frontotemporal dementia
and Alzheimer’s disease. This scientific approach is also the basis
for the company’s immuno-oncology programs. Alector is
headquartered in South San Francisco, California. For additional
information, please visit www.alector.com.
Alector ContactsMichelle CorralVP,
Communications and Investor
Relations650-808-7016michelle.corral@alector.com
1AB (media)Dan Budwick973-271-6085dan@1abmedia.com
Argot Partners (investors)Laura Perry/Eric KasperArgot
Partners212.600.1902alector@argotpartners.com
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Apr 2023 to Apr 2024